This company has been marked as potentially delisted and may not be actively trading. Stellar Biotechnologies (SBOT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock SBOT vs. AVTE, NLTX, BIOA, CYBN, VIRI, WHWK, ELYM, OSTX, ATNM, and NBRVShould you be buying Stellar Biotechnologies stock or one of its competitors? The main competitors of Stellar Biotechnologies include Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), Cybin (CYBN), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), Eliem Therapeutics (ELYM), OS Therapies (OSTX), Actinium Pharmaceuticals (ATNM), and Nabriva Therapeutics (NBRV). Stellar Biotechnologies vs. Its Competitors Aerovate Therapeutics Neoleukin Therapeutics BioAge Labs Cybin Virios Therapeutics Whitehawk Therapeutics Eliem Therapeutics OS Therapies Actinium Pharmaceuticals Nabriva Therapeutics Aerovate Therapeutics (NASDAQ:AVTE) and Stellar Biotechnologies (NASDAQ:SBOT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment. Do insiders and institutionals believe in AVTE or SBOT? 1.7% of Stellar Biotechnologies shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by insiders. Comparatively, 7.8% of Stellar Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media favor AVTE or SBOT? In the previous week, Aerovate Therapeutics had 2 more articles in the media than Stellar Biotechnologies. MarketBeat recorded 2 mentions for Aerovate Therapeutics and 0 mentions for Stellar Biotechnologies. Aerovate Therapeutics' average media sentiment score of 1.67 beat Stellar Biotechnologies' score of 0.00 indicating that Aerovate Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Aerovate Therapeutics Very Positive Stellar Biotechnologies Neutral Which has preferable earnings and valuation, AVTE or SBOT? Stellar Biotechnologies has higher revenue and earnings than Aerovate Therapeutics. Stellar Biotechnologies is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAerovate TherapeuticsN/AN/A-$75.52M-$1.70-4.56Stellar Biotechnologies$210K289.34-$5.03M-$1.76-6.48 Is AVTE or SBOT more profitable? Aerovate Therapeutics has a net margin of 0.00% compared to Stellar Biotechnologies' net margin of -1,782.64%. Stellar Biotechnologies' return on equity of -51.12% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aerovate TherapeuticsN/A -90.19% -77.47% Stellar Biotechnologies -1,782.64%-51.12%-48.37% SummaryAerovate Therapeutics beats Stellar Biotechnologies on 6 of the 11 factors compared between the two stocks. Get Stellar Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for SBOT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBOT vs. The Competition Export to ExcelMetricStellar BiotechnologiesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$60.76M$862.73M$5.79B$10.15BDividend YieldN/A4.84%5.69%4.60%P/E Ratio-6.481.1574.5925.92Price / Sales289.3427.04453.5485.33Price / CashN/A19.5637.0859.91Price / Book5.386.6912.156.29Net Income-$5.03M-$4.50M$3.28B$270.77M Stellar Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBOTStellar BiotechnologiesN/A$11.40+6.8%N/A+58.8%$60.76M$210K-6.4825High Trading VolumeAVTEAerovate TherapeuticsN/A$7.48-3.7%N/A-88.7%$216.81MN/A-2.5020Positive NewsHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$19.45-2.5%N/A-52.7%$182.79MN/A-6.2590High Trading VolumeBIOABioAge Labs0.1903 of 5 stars$4.98-2.2%N/AN/A$178.53M$3.86M0.00N/ACYBNCybin2.6847 of 5 stars$6.43+2.6%$85.00+1,221.9%N/A$151.68MN/A-1.4750High Trading VolumeVIRIVirios TherapeuticsN/A$4.90flat$5.00+2.0%+2,498.9%$94.36MN/A-18.155WHWKWhitehawk Therapeutics1.1969 of 5 stars$1.80+0.6%N/AN/A$84.83M$25.98M-30.0021Positive NewsGap DownELYMEliem TherapeuticsN/A$2.47+3.3%N/A-69.8%$73.49MN/A-4.669Gap UpOSTXOS Therapies1.7726 of 5 stars$2.19-2.2%$18.00+721.9%-34.2%$69.30MN/A-2.77N/AAnalyst ForecastATNMActinium Pharmaceuticals3.0655 of 5 stars$1.60flat$4.50+181.3%-13.8%$49.91MN/A-1.1530Positive NewsShort Interest ↑NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070 Related Companies and Tools Related Companies AVTE Competitors NLTX Competitors BIOA Competitors CYBN Competitors VIRI Competitors WHWK Competitors ELYM Competitors OSTX Competitors ATNM Competitors NBRV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SBOT) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored6-Figure Target for BTC by 2025Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stellar Biotechnologies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Stellar Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
